Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Tuesday, October 14, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has announced its selection for a late-breaking oral presentation regarding PBGENE-HBV at AASLD The Liver Meeting 2025. This recognition underscores the company's innovative approach in gene editing therapies. The event is significant for showcasing advancements in treatments for high unmet need diseases.
Price reaction · baseline $5.56 (2025-10-13 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
+5.2%
day 1
+16.9%
day 3 · peak
+24.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences has been selected for a late-breaking presentation.
  • The presentation is at a prestigious event, AASLD The Liver Meeting 2025.
  • Focus on PBGENE-HBV highlights advancements in gene editing therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Oct. 14, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to

Frequently Asked Questions

What is PBGENE-HBV?

PBGENE-HBV is a gene editing therapy developed by Precision BioSciences targeting hepatitis B.

Where will the presentation take place?

The presentation will occur at AASLD The Liver Meeting 2025.

What platform does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing.

What is the significance of this presentation?

The presentation highlights advancements in therapies for high unmet need diseases.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences PBGENE-HBV AASLD 2025 gene editing
Last updated: Oct 14, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →